Zeteo Tech Raises $3.5M in Series A Funding Round

 In News

SYKESVILLE, Md., April 15, 2019 /PRNewswire/ — Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, today announced that it has raised $3.5 million in seed stage funding from industrial technology venture capital firm Anzu Partners. The funding will be used for the continued development of its digitalMALDI® technology and the commercialization of its biological mass spectrometers used to identify airborne infectious disease and bio-terror threats.

“Zeteo Tech’s mass spectrometry systems enable fully-automated and near real-time identification of bio-threats in operational environments, said Dr. Wayne Bryden, President and CEO of Zeteo Tech. “This infusion of capital from Anzu Partners will help us accelerate our commercialization timeline to ensure our compact, low-power instruments can be deployed to the applications and geographical regions that need it the most.”

Zeteo Tech’s digitalMALDI® technology pushes the innovation to a whole new level of sensitivity and specificity, enabling its instruments to obtain biomarker measurements from individual particles in the bioaerosol and then complete a biomarker-specific molecular identification in seconds A combination of proprietary bioaerosol processing and MALDI mass spectrometry enables the technology’s ground-breaking advances to eliminate environmental background. By discretizing the sample in time, the analysis is exceptionally fast, sensitive and specific.

For more information about Zeteo Tech, please visit https://zeteotech.com.

About Zeteo Tech
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Its instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats. Its innovative and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully-automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being launched for biodefense applications.

About Anzu Partners
Anzu Partners is a venture capital and private equity firm that invests in breakthrough industrial technologies. Anzu teams with entrepreneurs to develop and commercialize technological innovations by providing capital and deep expertise in business development, market positioning, global connectivity, and operations. For more information, please visit https://anzupartners.com. On Twitter: @anzupartners.